2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons

Psychopharmacology

Volumn 232, Issue 15, 2015, Pages 2811-2825

  Llorente Berzal, Alvaro ^a,f   Terzian, Ana Luisa B ^b,c   Di Marzo, Vincenzo ^d   Micale, Vincenzo ^b,e   Viveros, Maria Paz ^a,f   Wotjak, Carsten T ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d CNR   (Italy)

^e MASARYK UNIVERSITY   (Czech Republic)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

AM404; Anandamide; CB1; CB2; Fear extinction; JZL184; TRPV1; URB597

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID RECEPTOR; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; RIMONABANT; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; N-(2-METHYL-3-HYDROXYPHENYL)-5,8,11,14-EICOSATETRAENAMIDE; N-(4-HYDROXYPHENYL)ARACHIDONYLAMIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DEGRADATION KINETICS; FACIAL EXPRESSION; FEAR; GLUTAMATERGIC NERVE CELL; INTRACELLULAR SIGNALING; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EMOTION; METABOLISM;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; EMOTIONS; ENDOCANNABINOIDS; FEAR; GABAERGIC NEURONS; GLYCERIDES; MALE; MICE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 84937726636     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-015-3917-y     Document Type: Article

References (96)

1. Aguiar DC, Moreira FA, Terzian AL, Fogaça MV, Lisboa SF, Wotjak CT et al (2014) Modulation of defensive behavior by transient receptor potential vanilloid type-1 (TRPV1) channels. Neurosci Biobehav Rev. doi: 10.1016/j.neubiorev.2014.03.026
2. Alger BE, Kim J (2011) Supply and demand for endocannabinoids. Trends Neurosci 34:304-315. doi: 10.1016/j.tins.2011.03.003
3. Aliczki M, Zelena D, Mikics E, Varga ZK, Pinter O, Bakos NV et al (2013) Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice. Horm Behav 63:752-758. doi: 10.1016/j.yhbeh.2013.03.017
4. Almeida-Santos AF, Gobira PH, Rosa LC, Guimaraes FS, Moreira FA, Aguiar DC (2013) Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray. Behav Brain Res 252:10-17. doi: 10.1016/j.bbr.2013.05.027
5. Andero R, Ressler KJ (2012) Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav 11:503-512. doi: 10.1111/j.1601-183X.2012.00801.x
6. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160:467-479
7. Bellocchio L, Lafenêtre P, Cannich A, Cota D, Puente N, Grandes P et al (2010) Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 13:281-283. doi: 10.1038/nn.2494
8. Beltramo M, Piomelli D (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport 11:1231-1235
9. Bisogno T, MacCarrone M, De Petrocellis L, Jarrahian A, Finazzi-Agrò A, Hillard C et al (2001) The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 268:1982-1989
10. Bitencourt RM, Pamplona FA, Takahashi RN (2008) Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849-859. doi: 10.1016/j.euroneuro.2008.07.001
11. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479-486. doi: 10.1016/j.biopsych.2011.04.022
12. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005) Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30:516-524. doi: 10.1038/sj.npp.1300655
13. de Bitencourt RM, Pamplona FA, Takahashi RN (2013) A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. Neuropharmacology 64:389-395. doi: 10.1016/j.neuropharm.2012.05.039
14. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52-56
15. Deussing JM (2013) Targeted mutagenesis tools for modelling psychiatric disorders. Cell Tissue Res 354:9-25. doi: 10.1007/s00441-013-1708-5
16. Dhopeshwarkar A, Mackie K (2014) CB2 Cannabinoid receptors as a therapeutic target - what does the future hold? Mol Pharmacol 86:430-437. doi: 10.1124/mol.114.094649
17. Di Marzo V (2011) Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nat Neurosci 14:9-15. doi: 10.1038/nn.2720
18. Dias BG, Banerjee SB, Goodman JV, Ressler KJ (2013) Towards new approaches to disorders of fear and anxiety. Curr Opin Neurobiol 23:346-352. doi: 10.1016/j.conb.2013.01.013
19. Edwards JG, Gibson HE, Jensen T, Nugent F, Walther C, Blickenstaff J et al (2012) A novel non-CB1/TRPV1 endocannabinoid-mediated mechanism depresses excitatory synapses on hippocampal CA1 interneurons. Hippocampus 22:209-221. doi: 10.1002/hipo.20884
20. Fowler CJ (2012) Anandamide uptake explained? Trends Pharmacol Sci 33:181-185. doi: 10.1016/j.tips.2012.01.001
21. Fowler CJ (2013) Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J 280:1895-1904. doi: 10.1111/febs.12212
22. Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M et al (2012) A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci 15:64-69. doi: 10.1038/nn.2986
23. Ganon-Elazar E, Akirav I (2013) Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit. Psychoneuroendocrinology 38:1675-1687. doi: 10.1016/j.psyneuen.2013.01.014
24. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M et al (2010) Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30:2017-2024. doi: 10.1523/JNEUROSCI. 5693-09.2010
25. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003) Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100:4269-4274. doi: 10.1073/pnas.0730816100
26. Golub Y, Mauch CP, Dahlhoff M, Wotjak CT (2009) Consequences of extinction training on associative and non-associative fear in a mouse model of posttraumatic stress disorder (PTSD). Behav Brain Res 205:544-549. doi: 10.1016/j.bbr.2009.08.019
27. Graham BM, Milad MR (2011) The study of fear extinction: implications for anxiety disorders. Am J Psychiatry 168:1255-1265. doi: 10.1176/appi.ajp.2011.11040557
28. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F et al (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20:441-458. doi: 10.1111/j.1460-9568.2004.03428.x
29. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013a) Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34:637-644. doi: 10.1016/j.tips.2013.08.008
30. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B et al (2013b) Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18:813-823. doi: 10.1038/mp.2012.72
31. Haller J, Varga B, Ledent C, Freund TF (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15:299-304
32. Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F et al (2012) Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148:1039-1050. doi: 10.1016/j.cell.2012.01.037
33. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F et al (2009) Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry 66:9-16. doi: 10.1016/j.biopsych.2008.10.047
34. Hashimotodani Y, Ohno-Shosaku T, Kano M (2007) Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J Neurosci 27:1211-1219. doi: 10.1523/JNEUROSCI. 4159-06.2007
35. Heitland I, Klumpers F, Oosting RS, Evers DJ, Leon Kenemans J, Baas JM (2012) Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. Transl Psychiatry 2:e162. doi: 10.1038/tp.2012.90
36. Heldt SA, Mou L, Ressler KJ (2012) In vivo knockdown of GAD67 in the amygdala disrupts fear extinction and the anxiolytic-like effect of diazepam in mice. Transl Psychiatry 2:e181. doi: 10.1038/tp.2012.101
37. Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS (2010) Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 30:14980-14986. doi: 10.1523/JNEUROSCI. 4283-10.2010
38. Hillard CJ (2014) Stress regulates endocannabinoid-CB1 receptor signaling. Semin Immunol. doi: 10.1016/j.smim.2014.04.001
39. Hillard CJ, Weinlander KM, Stuhr KL (2012) Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204:207-229. doi: 10.1016/j.neuroscience.2011.11.020
40. Holmes A, Singewald N (2013) Individual differences in recovery from traumatic fear. Trends Neurosci 36:23-31. doi: 10.1016/j.tins.2012.11.003
41. Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT (2009) Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 8:685-698. doi: 10.1111/j.1601-183X.2009.00512.x
42. Jacob W, Marsch R, Marsicano G, Lutz B, Wotjak CT (2012) Cannabinoid CB1 receptor deficiency increases contextual fear memory under highly aversive conditions and long-term potentiation in vivo. Neurobiol Learn Mem 98:47-55. doi: 10.1016/j.nlm.2012.04.008
43. Kamprath K, Wotjak CT (2004) Nonassociative learning processes determine expression and extinction of conditioned fear in mice. Learn Mem 11:770-786. doi: 10.1101/lm.86104
44. Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo V et al (2006) Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 26:6677-6686. doi: 10.1523/JNEUROSCI. 0153-06.2006
45. Kamprath K, Plendl W, Marsicano G, Deussing JM, Wurst W, Lutz B et al (2009) Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav 8:203-211. doi: 10.1111/j.1601-183X.2008.00463.x
46. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A et al (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81. doi: 10.1038/nm803
47. Kearns MC, Ressler KJ, Zatzick D, Rothbaum BO (2012) Early interventions for PTSD: a review. Depress Anxiety 29:833-842. doi: 10.1002/da.21997
48. Kim J, Alger BE (2004) Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7:697-698. doi: 10.1038/nn1262
49. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2011) Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21-27. doi: 10.1016/j.pbb.2010.12.002
50. Lafenêtre P, Chaouloff F, Marsicano G (2009) Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system. Neuropharmacology 57:715-721. doi: 10.1016/j.neuropharm.2009.07.014
51. Llorente-Berzal A, Fuentes S, Gagliano H, López-Gallardo M, Armario A, Viveros MP et al (2011) Sex-dependent effects of maternal deprivation and adolescent cannabinoid treatment on adult rat behaviour. Addict Biol 16:624-637. doi: 10.1111/j.1369-1600.2011.00318.x
52. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44. doi: 10.1038/nchembio.129
53. Luchicchi A, Pistis M (2012) Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. Mol Neurobiol 46:374-392. doi: 10.1007/s12035-012-8299-0
54. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A et al (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11:152-159. doi: 10.1038/nn2042
55. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316:969-982. doi: 10.1124/jpet.105.093286
56. Maione S, Costa B, Piscitelli F, Morera E, De Chiaro M, Comelli F et al (2013) Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. Pharmacol Res 76C:98-105. doi: 10.1016/j.phrs.2013.07.003
57. Manwell LA, Satvat E, Lang ST, Allen CP, Leri F, Parker LA (2009) FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav 94:154-162. doi: 10.1016/j.pbb.2009.08.002
58. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F et al (2007) Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 27:832-839. doi: 10.1523/JNEUROSCI. 3303-06.2007
59. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225
60. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534. doi: 10.1038/nature00839
61. McGregor IS, Issakidis CN, Prior G (1996) Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav 53:657-664
62. Mechoulam R, Parker LA (2013) The endocannabinoid system and the brain. Annu Rev Psychol 64:21-47. doi: 10.1146/annurev-psych-113011-143739
63. 1 cannabinoid receptors. J Neurosci 32:7109-7118. doi: 10.1523/JNEUROSCI.1054-12.2012
64. Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F (2013) Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther 138:18-37. doi: 10.1016/j.pharmthera.2012.12.002
65. Monory K, Massa F, Egertová M, Eder M, Kelsch W, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein J, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls a key epileptogenic circuit in the hippocampus. Neuron 51:455-466
66. Moreira FA, Wotjak CT (2010) Cannabinoids and anxiety. Curr Top Behav Neurosci 2:429-450
67. Moreira FA, Aguiar DC, Terzian AL, Guimarães FS, Wotjak CT (2012) Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety - two sides of one coin? Neuroscience 204:186-192. doi: 10.1016/j.neuroscience.2011.08.046
68. Morena M, Roozendaal B, Trezza V, Ratano P, Peloso A, Hauer D et al (2014) Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training. Proc Natl Acad Sci U S A 111:18333-18338
69. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61-70. doi: 10.1007/s00213-006-0689-4
70. Niyuhire F, Varvel SA, Martin BR, Lichtman AH (2007) Exposure to marijuana smoke impairs memory retrieval in mice. J Pharmacol Exp Ther 322:1067-1075. doi: 10.1124/jpet.107.119594
71. Pamplona FA, Prediger RD, Pandolfo P, Takahashi RN (2006) The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology (Berl) 188:641-649. doi: 10.1007/s00213-006-0514-0
72. Pamplona FA, Bitencourt RM, Takahashi RN (2008) Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem 90:290-293. doi: 10.1016/j.nlm.2008.04.003
73. Pan B, Wang W, Zhong P, Blankman JL, Cravatt BF, Liu QS (2011) Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J Neurosci 31:13420-13430. doi: 10.1523/JNEUROSCI. 2075-11.2011
74. Pardini M, Krueger F, Koenigs M, Raymont V, Hodgkinson C, Zoubak S et al (2012) Fatty-acid amide hydrolase polymorphisms and post-traumatic stress disorder after penetrating brain injury. Transl Psychiatry 2:e75. doi: 10.1038/tp.2012.1
75. Parsons RG, Ressler KJ (2013) Implications of memory modulation for post-traumatic stress and fear disorders. Nat Neurosci 16:146-153. doi: 10.1038/nn.3296
76. Patel S, Roelke CT, Rademacher DJ, Hillard CJ (2005) Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 21:1057-1069. doi: 10.1111/j.1460-9568.2005.03916.x
77. Plendl W, Wotjak CT (2010) Dissociation of within- and between-session extinction of conditioned fear. J Neurosci 30:4990-4998. doi: 10.1523/JNEUROSCI. 6038-09.2010
78. Ralevic V, Kendall DA, Jerman JC, Middlemiss DN, Smart D (2001) Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol 424:211-219
79. Rea K, Ford GK, Olango WM, Harhen B, Roche M, Finn DP (2014) Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. Eur J Neurosci 39:435-443
80. Rey AA, Purrio M, Viveros MP, Lutz B (2012) Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37:2624-2634. doi: 10.1038/npp.2012.123
81. Riebe CJ, Pamplona FA, Pamplona F, Kamprath K, Wotjak CT (2012) Fear relief - toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 204:159-185. doi: 10.1016/j.neuroscience.2011.11.057
82. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ et al (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132:631-640. doi: 10.1038/sj.bjp.0703850
83. Savinainen JR, Saario SM, Laitinen JT (2012) The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) 204:267-276. doi: 10.1111/j.1748-1716.2011.02280.x
84. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG et al (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113-1119. doi: 10.1038/nn.2616
85. Sciolino NR, Zhou W, Hohmann AG (2011) Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64:226-234. doi: 10.1016/j.phrs.2011.04.010
86. Siegmund A, Wotjak CT (2007) A mouse model of posttraumatic stress disorder that distinguishes between conditioned and sensitised fear. J Psychiatr Res 41:848-860. doi: 10.1016/j.jpsychires.2006.07.017
87. Siegmund A, Langnaese K, Wotjak CT (2005) Differences in extinction of conditioned fear in C57BL/6 substrains are unrelated to expression of alpha-synuclein. Behav Brain Res 157:291-298. doi: 10.1016/j.bbr.2004.07.007
88. Suárez J, Ortíz O, Puente N, Bermúdez-Silva FJ, Blanco E, Fernández-Llebrez P et al (2011) Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain. Neuroscience 192:112-131. doi: 10.1016/j.neuroscience.2011.06.062
89. Tambaro S, Bortolato M (2012) Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov 7:25-40
90. Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M et al (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65:320-327. doi: 10.1016/j.neuron.2010.01.021
91. Trezza V, Campolongo P (2013) The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front Behav Neurosci 7:100. doi: 10.3389/fnbeh.2013.00100
92. Uchigashima M, Yamazaki M, Yamasaki M, Tanimura A, Sakimura K, Kano M et al (2011) Molecular and morphological configuration for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-granule cell synapses in the dentate gyrus. J Neurosci 31:7700-7714. doi: 10.1523/JNEUROSCI. 5665-10.2011
93. Wiskerke J, Irimia C, Cravatt BF, De Vries TJ, Schoffelmeer AN, Pattij T et al (2012) Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study. ACS Chem Neurosci 3:407-417. doi: 10.1021/cn300036b
94. Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M et al (2006) Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 26:4740-4751. doi: 10.1523/JNEUROSCI. 0054-06.2006
95. Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D et al (2011) Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J Physiol 589:4857-4884. doi: 10.1113/jphysiol.2011.212225
96. Zygmunt PM, Chuang H, Movahed P, Julius D, Högestätt ED (2000) The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396:39-42